M&A / Deals LG AI Research and D&D Pharmatech sign agreement for oral peptide drugs pharminent June 18, 2026
M&A / Deals Merck adds to biopharma’s AI agenda with up to $510M+ Protillion pact pharminent June 17, 2026
M&A / Deals Sky-high Parabilis, Kailera IPOs spur optimism–but only for derisked biotechs pharminent June 11, 2026
M&A / Deals Beren pockets $300m to take Niemann-Pick disease therapy to market pharminent June 11, 2026
M&A / Deals Alzecure enters collaboration and with Lilly for Alzheimer’s project pharminent June 9, 2026
M&A / Deals GSK pays $10.6B for cancer biotech Nuvalent in industry’s second-biggest buy of the year pharminent June 9, 2026
M&A / Deals J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1B pharminent June 8, 2026
M&A / Deals Regeneron deepens relationship with CytomX, adding up to $2B and eight targets pharminent June 4, 2026
M&A / Deals Eli Lilly continues genetic medicine push with $1.9bn Ascidian partnership pharminent June 4, 2026
M&A / Deals Travere beefs up rare kidney disease portfolio with up to $1.1B China deal pharminent June 3, 2026
M&A / Deals Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug pharminent June 2, 2026
M&A / Deals Deep Science Ventures and MDC partner to accelerate brain treatments pharminent June 2, 2026
M&A / Deals Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn pharminent June 2, 2026
M&A / Deals CordenPharma inks AmbioPharm buyout to continue peptide production expansion pharminent June 1, 2026
M&A / Deals Pfizer bets up to $10.5B in 12-candidate cancer collab with China’s Innovent pharminent May 29, 2026
M&A / Deals Apogee investors riled by $1.3B royalty deal, as eczema drug matches Lilly’s Ebglyss pharminent May 27, 2026
M&A / Deals Gilead inks $140M API supply deal, tightening ties to Korean manufacturer pharminent May 22, 2026
